Topography of neovascularity in human prostate carcinoma.
about
The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways.Angiogenesis in urological malignancy: prognostic indicator and therapeutic target.Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.The use of microvessel density in assessing human urological tumours.Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts.Going malignant: the hypoxia-cancer connection in the prostate.Evidence for field cancerization of the prostate.Markers of field cancerization: proposed clinical applications in prostate biopsiesDynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer.The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting.Multiparametric MRI of the prostate gland: technical aspects.DCE MRI of prostate cancer.Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.Arterial input functions (AIFs) measured directly from arteries with low and standard doses of contrast agent, and AIFs derived from reference tissues.Contrast-enhanced transrectal ultrasonography of a novel canine prostate cancer model.Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber.Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma.Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.Current prostate biopsy protocols cannot reliably identify patients for focal therapy: correlation of low-risk prostate cancer on biopsy with radical prostatectomy findings.Vascular pericyte density and angiogenesis associated with adenocarcinoma of the prostate.Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer.Profiling Prostate Cancer Therapeutic Resistance.Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
P2860
Q27687896-C8169012-F695-4ACF-B016-E827BDC50A53Q33598141-537ECB40-3298-4BCE-96A1-4E284180B0CEQ33847495-A80B2730-8FAD-4A02-B80B-5824136DA0E3Q34285922-E386453E-819C-4B3E-8B23-906DFE9FEC51Q34779401-545126EF-ED60-49CB-AC41-18880D0117BEQ34811618-D920C8CE-EFF1-4BFD-9C41-085916E313DCQ34982560-87F55048-E4FC-4AE3-8AFE-62EAC0E3FF3DQ35991148-CF763357-E667-43D2-9441-438B60461574Q37721529-382D8DD6-6A17-469B-ACA0-39D6B11D1F10Q37823843-70E3C1F6-2202-4502-B102-436332D73D2DQ38088721-EC6833C8-363D-4C3C-A973-8C28F4763EF6Q38207448-0C38F79F-37F9-4887-A6E8-B8EA5E66D250Q38457725-F8DFDAF0-973F-4F11-BEE8-720122692CD8Q38470808-2D4A8666-DB21-49CE-86B3-E2346D1AE484Q38830576-49543726-6F66-4C99-8C54-ADFE5ACCC315Q38837802-A2A7EBBE-615E-4155-A888-B411B13F36D3Q39816598-4B7933E1-FCB3-4072-9256-661D42759E6BQ40367878-B6E1C0BB-FC7C-4125-811A-FB1B50A21998Q40705807-097FC289-B651-4509-A2A8-9D74EE5D22A8Q40862919-DC1BCB52-8599-4DA3-9DDC-8068ADD2223FQ40933435-E093D8CE-740E-498D-B07E-6C3E34C59DB8Q41778639-033083DB-3059-48F9-BB20-83FDF6D7DC36Q41906180-0473067F-CE97-4365-90EF-82227C92F3B5Q45755546-C5D37557-630C-49B1-967B-F0BE805151EEQ47399778-22E03938-53E6-4032-8525-5DBE05A5B26EQ52644478-22984832-C6AA-48D0-87CF-359FC6355EC0Q58212129-3DDD4717-DA80-4A82-8EFE-5E8BD6F9E9CF
P2860
Topography of neovascularity in human prostate carcinoma.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Topography of neovascularity in human prostate carcinoma.
@en
Topography of neovascularity in human prostate carcinoma.
@nl
type
label
Topography of neovascularity in human prostate carcinoma.
@en
Topography of neovascularity in human prostate carcinoma.
@nl
prefLabel
Topography of neovascularity in human prostate carcinoma.
@en
Topography of neovascularity in human prostate carcinoma.
@nl
P2093
P1433
P1476
Topography of neovascularity in human prostate carcinoma.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(19950515)75:10<2545::AID-CNCR2820751022>3.0.CO;2-X
P407
P577
1995-05-01T00:00:00Z